Guggenheim Increases Regeneron Pharmaceuticals (NASDAQ:REGN) Price Target to $1,300.00

Regeneron Pharmaceuticals (NASDAQ:REGN) had its price objective raised by Guggenheim from $1,180.00 to $1,300.00 in a research report released on Friday, Benzinga reports. The brokerage currently has a buy rating on the biopharmaceutical company’s stock.

A number of other analysts also recently commented on REGN. Piper Sandler raised their price objective on Regeneron Pharmaceuticals from $1,000.00 to $1,166.00 and gave the stock an overweight rating in a research report on Friday, July 19th. StockNews.com downgraded Regeneron Pharmaceuticals from a strong-buy rating to a buy rating in a research report on Tuesday, April 30th. Evercore ISI began coverage on Regeneron Pharmaceuticals in a research report on Tuesday, May 14th. They issued an outperform rating and a $1,150.00 price objective for the company. Royal Bank of Canada reiterated an outperform rating and issued a $1,229.00 price objective on shares of Regeneron Pharmaceuticals in a research report on Monday, June 24th. Finally, UBS Group lifted their price objective on Regeneron Pharmaceuticals from $1,090.00 to $1,099.00 and gave the company a buy rating in a research report on Wednesday, April 17th. One equities research analyst has rated the stock with a sell rating, four have given a hold rating, seventeen have given a buy rating and two have assigned a strong buy rating to the stock. Based on data from MarketBeat.com, Regeneron Pharmaceuticals presently has an average rating of Moderate Buy and an average target price of $1,097.05.

Regeneron Pharmaceuticals Stock Performance

REGN opened at $1,071.28 on Friday. The firm has a market capitalization of $118.04 billion, a P/E ratio of 31.65, a price-to-earnings-growth ratio of 2.34 and a beta of 0.13. The stock’s 50 day moving average price is $1,043.43 and its two-hundred day moving average price is $983.16. The company has a quick ratio of 4.51, a current ratio of 5.96 and a debt-to-equity ratio of 0.10. Regeneron Pharmaceuticals has a 12-month low of $765.28 and a 12-month high of $1,115.00.

Regeneron Pharmaceuticals (NASDAQ:REGN) last released its earnings results on Thursday, August 1st. The biopharmaceutical company reported $11.56 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $8.93 by $2.63. Regeneron Pharmaceuticals had a return on equity of 16.80% and a net margin of 32.04%. The firm had revenue of $3.55 billion for the quarter, compared to analyst estimates of $3.38 billion. During the same quarter last year, the firm posted $8.79 EPS. The company’s revenue was up 12.3% on a year-over-year basis. On average, equities analysts forecast that Regeneron Pharmaceuticals will post 37.38 earnings per share for the current year.

Insiders Place Their Bets

In other Regeneron Pharmaceuticals news, Director Arthur F. Ryan sold 100 shares of the stock in a transaction dated Monday, July 1st. The stock was sold at an average price of $1,059.24, for a total value of $105,924.00. Following the completion of the sale, the director now directly owns 17,882 shares in the company, valued at $18,941,329.68. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. In other news, Director Bonnie L. Bassler sold 827 shares of the company’s stock in a transaction dated Wednesday, June 5th. The stock was sold at an average price of $1,011.00, for a total transaction of $836,097.00. Following the completion of the transaction, the director now directly owns 1,382 shares of the company’s stock, valued at $1,397,202. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. Also, Director Arthur F. Ryan sold 100 shares of the company’s stock in a transaction dated Monday, July 1st. The stock was sold at an average price of $1,059.24, for a total value of $105,924.00. Following the transaction, the director now directly owns 17,882 shares of the company’s stock, valued at $18,941,329.68. The disclosure for this sale can be found here. Insiders sold 65,074 shares of company stock worth $64,546,123 over the last ninety days. 7.48% of the stock is currently owned by corporate insiders.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently modified their holdings of the company. Atria Investments Inc boosted its position in shares of Regeneron Pharmaceuticals by 12.2% during the first quarter. Atria Investments Inc now owns 8,657 shares of the biopharmaceutical company’s stock worth $8,317,000 after buying an additional 941 shares during the period. Nordea Investment Management AB boosted its position in shares of Regeneron Pharmaceuticals by 23.2% during the first quarter. Nordea Investment Management AB now owns 29,195 shares of the biopharmaceutical company’s stock worth $28,218,000 after buying an additional 5,495 shares during the period. Tidal Investments LLC boosted its position in shares of Regeneron Pharmaceuticals by 16.8% during the first quarter. Tidal Investments LLC now owns 4,955 shares of the biopharmaceutical company’s stock worth $4,774,000 after buying an additional 711 shares during the period. Sierra Summit Advisors LLC acquired a new position in Regeneron Pharmaceuticals during the fourth quarter valued at approximately $1,011,000. Finally, Susquehanna Fundamental Investments LLC acquired a new position in Regeneron Pharmaceuticals during the first quarter valued at approximately $1,232,000. 83.31% of the stock is owned by institutional investors and hedge funds.

Regeneron Pharmaceuticals Company Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.